PEGASYS 180 MCG/0.5 ML

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

PEGINTERFERON ALFA 2A 180 MCG / 0.5 ML

Disponibbli minn:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

Kodiċi ATC:

L03AB11

Għamla farmaċewtika:

SOLUTION FOR INJECTION

Rotta amministrattiva:

S.C

Manifatturat minn:

HOFFMANN LA ROCHE LTD, SWITZERLAND

Grupp terapewtiku:

PEGINTERFERON ALFA-2A

Indikazzjonijiet terapewtiċi:

Chronic Hepatitis B: Pegasys is indicated for the treatment of both HBeAg- positive and HBeAg -negative chronic hepatitis B in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.Chronic Hepatitis C: Pegasys is indicated for the treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA including patients with compensated cirrhosis and/or co-infected with clinically stable HIV. The optimal way to use Pegasys in patients with chronic hepatitis C is in combination with ribavirin. The combination of Pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

Data ta 'l-awtorizzazzjoni:

2013-09-01